Clinical Trial

A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV)

Study acronym: REVIVE-HEART
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this clinical study is to evaluate the efficacy and safety of intramyocardial injection of human induced pluripotent stem cell-derived cardiomyocyte injection (HiCM-188) in patients with advanced heart failure (NYHA Class III-IV)
Protocol Amendment History 2 changes
critical Recruitment opened 2026-04-04
notable Sponsor changed: Help Therapeutics -> HELP Therapeutics Co., Ltd. 2026-04-04
Trial Details
NCT Number NCT07496372
Lead Sponsor HELP Therapeutics Co., Ltd.
Conditions Heart Failure
Enrollment 80 participants
Start Date 2026-04-30
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-12